Latest Sulfonylurea Stories
RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 21, 2014 /PRNewswire/ -- The U.S.
Prescribers Are Enthusiastic about the SGLT-2 Inhibitors, but Payers Are Not Fully Convinced of the Added Benefits of These Agents, According to Findings from Decision Resources Group BURLINGTON,
A large-scale study from Cardiff University reveals that people with Type 2 diabetes can live longer than those without the condition, thanks to a widely prescribed blood glucose control medication.
In Phase 3 studies, INVOKANA® plus metformin lowered blood sugar and reduced secondary endpoints of body weight and systolic blood pressure to a greater degree than metformin alone RARITAN,
SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Data from a new phase 3 study demonstrated that once-daily Victoza(R) (liraglutide [rDNA origin] injection) provided greater
SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- New Phase 3a findings show IDegLira, the investigational once-daily single injection combination of insulin degludec and liraglutide,
ROCKVILLE, Md., June 10, 2014 /PRNewswire-USNewswire/ -- Patients with type 2 diabetes who take a combination of metformin plus insulin may be at higher risk for cardiovascular disease and death
MISSISSAUGA, ON, June 4, 2014 /CNW/ - Novo Nordisk today announces that the Québec government has approved the inclusion of Victoza(®) (liraglutide), the first once-daily human glucagon-like
LONDON, April 15, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Tanzeum(TM) (albiglutide) for injection, for subcutaneous
Researchers say the diabetes drug does not appear to reduce the risk of bladder cancer in patients with type 2 diabetes. Raleigh, NC (PRWEB) February 14, 2014
- An imitative word; an onomatopoetic word.